Study S001363

Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04560998
Acronym: STRIDE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 792
Start: 2020-10-01
Primary completion: 2024-06-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2; Peripheral Arterial Disease
Interventions: DRUG:Semaglutide; DRUG:Placebo (semaglutide)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2019-003399-38; OTHER:U1111-1238-7071; NIH:2019

Registered primary outcomes

Change in Maximum Walking Distance on a Constant Load Treadmill Test [Baseline (week 0), end of treatment (week 52)]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014505	Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial. Nordanstig J, European heart journal	2026	Randomized trial	PMID 41780559 DOI	cites ClinicalTrials.gov:NCT04560998
R0004184	Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. Bonaca MP, European heart journal. Cardiovascular pharmacotherapy	2025	Protocol	PMID 39424598 DOI	cites ClinicalTrials.gov:NCT04560998
R0017068	Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. Rasouli N, Diabetes care	2025	Randomized trial	PMID 40543068 DOI	cites ClinicalTrials.gov:NCT04560998
R0018169	Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Bonaca MP, Lancet (London, England)	2025	Randomized trial	PMID 40169145 DOI	cites ClinicalTrials.gov:NCT04560998; registry reference DERIVED:40169145
R0049519	291-OR: Effect of Type 2 Diabetes Characteristics on Semaglutide Treatment in People with Type 2 Diabetes and Peripheral Artery Disease—A Post Hoc Analysis of the STRIDE Trial Neda Rasouli, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04560998
R0041799	Prevention is the key Stefan Agewall, European Heart Journal - Cardiovascular Pharmacotherapy	2024	Randomized trial	PMID 39797531 DOI	cites ClinicalTrials.gov:NCT04560998
R0016220	Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope? Caruso P, Diabetes/metabolism research and reviews	2023	Randomized trial	PMID 36812501 DOI	cites ClinicalTrials.gov:NCT04560998